Tag:

Novartis

Latest Headlines

Latest Headlines

The top 15 late-stage blockbusters in the pipeline

In recent years it's been the big biotechs in the U.S. which have registered approvals for the drugs most likely to succeed on the market. But in reviewing EvaluatePharma's recent picks for top Phase III drugs, it's interesting to see some prominent positions among the Big Pharma crowd. Read the full report >>

How big is Novartis' LCZ696 heart drug? Experts bet on a key number

In the pharma business, you're only as good as your next big blockbuster. And in Novartis' case, the next big cardio blockbuster--LCZ696--looks very good, indeed.

Novartis' U.S. Diovan plant gets 'For Sale' sign

When Novartis put a closure target on its plant in Suffern, NY, it indicated that it might go as far as to strip out the equipment, raze the buildings and sell empty land. But the 160-acre campus is now officially on the block and being brokered as a great buy for the right drug manufacturer.

U.K. and Novartis begin price negotiations on Bexsero

Let the negotiations begin. After pushing back on the price of Novartis' meningitis B vaccine, Bexsero, the U.K. is coming to the table with the Swiss drugmaker to see if it can haggle down the cost to its health system.

Novartis apologizes for lax business practices in Japan as side-effects scandal widens

Facing its second scandal in as many months, Novartis' Japanese unit has issued an apology for failing to disclose side effects of its drugs Tasigna and Gleevec, which are used to treat leukemia.

Novartis reports high Bexsero uptake as it pushes ahead in open market

With Novartis and Pfizer racing for approval in a wide-open U.S. market, the Swiss pharma is taking the opportunity to expand its lead elsewhere, where its vaccine, Bexsero, has an expansive patient pool all to itself. And so far, it's going well, Novartis says.

Quark's RNAi treatment misses the mark in a Phase II kidney trial

Quark Pharmaceuticals' gene-silencing treatment for kidney transplant complications missed its primary endpoint in a Phase II trial, possibly jeopardizing a deal with Novartis worth up to $680 million.

Roche, Novartis protest moves in EU to pay for off-label Avastin

Last week, France made its move to knock the Novartis eye drug Lucentis out of drug coverage and move its cheaper cousin Avastin into its place. Now, Novartis and its Lucentis partner Roche are fighting back.

FDA opens the door for a Novartis biosimilar of Amgen's Neupogen

The FDA accepted Novartis' application to sell a knockoff of Amgen's biological treatment Neupogen, making the company a pioneer among those looking to capitalize on a soon-to-come U.S. market for biosimilars that is expected to explode.

The top 5 vaccine makers by 2013 revenue

Vaccines, which can be complicated and expensive to manufacture, haven't always been the moneymakers they are for some drugmakers today. Last year, the global vaccines market topped $25.56 billion according to Evaluate Pharma, with the world's 6 top-selling shots each cracking the blockbuster barrier.